Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
Lisco, Giuseppe
;Piazzolla, Giuseppina;Guastamacchia, Edoardo;Sabbà, Carlo;Triggiani, Vincenzo
2023-01-01
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase the risk of papillary and medullary thyroid cancer. In this perspective, the role of the incretin system in thyroid carcinogenesis has been reviewed and critically commented on, aiming to understand if the time has arrived to be concerned about the risk. Although evidence suggested, speculative hypotheses should be verified, and further studies are urgently needed to clarify the issue.| File | Dimensione | Formato | |
|---|---|---|---|
|
endocrine connectionsLisco_ECC230257.pdf
accesso aperto
Descrizione: Review
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
458.92 kB
Formato
Adobe PDF
|
458.92 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
